ricul-1
ricul-1 / iStockphoto.com
8 September 2017Americas

Merck to acquire immuno-oncology firm for $137m

Merck has revealed plans to boost its immune-oncology expertise with the acquisition of Germany-based Rigontec.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
13 January 2014   Biopharmaceutical company Alnylam has paid Merck $175 million for its subsidiary Sirna Therapeutics, a firm specialising in RNA interference therapeutics.

More on this story

Americas
13 January 2014   Biopharmaceutical company Alnylam has paid Merck $175 million for its subsidiary Sirna Therapeutics, a firm specialising in RNA interference therapeutics.

More on this story

Americas
13 January 2014   Biopharmaceutical company Alnylam has paid Merck $175 million for its subsidiary Sirna Therapeutics, a firm specialising in RNA interference therapeutics.